Document is current
Any future updates will be listed below
-
Authors
Stamberger, Hannah
Hammer, Trine B.
Gardella, Elena
Vlaskamp, Danique R. M.
Bertelsen, Birgitte
Mandelstam, Simone
de Lange, Iris
Zhang, Jing
Myers, Candace T.
Fenger, Christina
Afawi, Zaid
Almanza Fuerte, Edith P.
Andrade, Danielle M.
Balcik, Yunus
Ben Zeev, Bruria
Bennett, Mark F.
Berkovic, Samuel F.
Isidor, Bertrand
Bouman, Arjan
Brilstra, Eva
Busk, Øyvind L.
Cairns, Anita
Caumes, Roseline
Chatron, Nicolas
Dale, Russell C.
de Geus, Christa
Edery, Patrick
Gill, Deepak
Granild-Jensen, Jacob Bie
Gunderson, Lauren
Gunning, Boudewijn
Heimer, Gali
Helle, Johan R.
Hildebrand, Michael S.
Hollingsworth, Georgie
Kharytonov, Volodymyr
Klee, Eric W.
Koeleman, Bobby P. C.
Koolen, David A.
Korff, Christian
Küry, Sébastien
Lesca, Gaetan
Lev, Dorit
Leventer, Richard J.
Mackay, Mark T.
Macke, Erica L.
McEntagart, Meriel
Mohammad, Shekeeb S.
Monin, Pauline
Montomoli, Martino
Morava, Eva
Moutton, Sebastien
Muir, Alison M.
Parrini, Elena
Procopis, Peter
Ranza, Emmanuelle
Reed, Laura
Reif, Philipp S.
Rosenow, Felix
Rossi, Massimiliano
Sadleir, Lynette G.
Sadoway, Tara
Schelhaas, Helenius J.
Schneider, Amy L.
Shah, Krati
Shalev, Ruth
Sisodiya, Sanjay M.
Smol, Thomas
Stumpel, Connie T. R. M.
Stuurman, Kyra
Symonds, Joseph D.
Mau-Them, Frederic Tran
Verbeek, Nienke
Verhoeven, Judith S.
Wallace, Geoffrey
Yosovich, Keren
Zarate, Yuri A.
Zerem, Ayelet
Zuberi, Sameer M.
Guerrini, Renzo
Mefford, Heather C.
Patel, Chirag
Zhang, Yue-Hua
Møller, Rikke S.
Scheffer, Ingrid E. http://orcid.org/0000-0002-2311-2174
-
License Information
Text and Data Mining valid from 2020-11-04
Version of Record valid from 2020-11-04
-
More Information
Article History
Received: 8 June 2020
Revised: 21 September 2020
Accepted: 21 September 2020
First Online: 4 November 2020
Disclosure
: R.G. has acted as an investigator for studies with Zogenix, Biocodex, Biomarin, UCB, Angelini, and Eisai Inc. He has been a speaker and on advisory boards for Zogenix, Biocodex, Novartis, Biomarin, GW Pharma, and Biocodex; serves/has served on the editorial boards of <i>Epilepsia</i>, <i>Progress in Epileptic Disorders</i>, <i>Neuropediatrics</i>, <i>Journal of Child Neurology</i>, <i>Seizure</i>, <i>BMC Medical Genetics</i>, <i>Topics in Epilepsy</i>, and <i>Neurology</i>. He receives/has received research support from the Italian Ministry of Health, The European Community, The Tuscany Region, the Mariani Foundation, The Pisa Foundation, The Fund of Epilepsy, The GKT Special Trustees, The Italian Federation for Epilepsy, and The Italian Association for Epilepsy. I.E.S. serves/has served on the editorial boards of the <i>Annals of Neurology</i>, <i>Neurology</i>, and <i>Epileptic Disorders</i>; may accrue future revenue on pending patent WO61/010176 (filed: 2008): Therapeutic Compound; has a patent for <i>SCN1A</i> testing held by Bionomics, Inc., and licensed to various diagnostic companies; has a patent molecular diagnostic/theranostic target for benign familial infantile epilepsy (BFIE) [PRRT2] 2011904493 & 2012900190 and PCT/AU2012/001321 (TECH ID:2012-009) with royalties paid. She has served on scientific advisory boards for UCB, Eisai, GlaxoSmithKline, BioMarin, Nutricia, Rogcon, and Xenon Pharmaceuticals; has received speaker honoraria from GlaxoSmithKline, UCB, BioMarin, Biocodex, and Eisai; has received funding for travel from UCB, Biocodex, GlaxoSmithKline, Biomarin, and Eisai; has served as an investigator for Zogenix, Zynerba, Ultragenyx, GW Pharma, UCB, Eisai, Anavex Life Scienand Marinus; and has consulted for Zynerba Pharmaceuticals, Atheneum Partners, Ovid Therapeutics, and UCB. She receives/has received research support from the National Health and Medical Research Council of Australia, Health Research Council of New Zealand, CURE, Australian Epilepsy Research Fund, March of Dimes and NIH/NINDS. D.M.A. has consulted for Eisai, UCB, and is part of the MAB of Stoke Therapeutics and DSF. B.G. has received consultancy fees from GW Pharmaceuticals companies, Zogenix, and Ovid/Takeda; and is a principal investigator for GW Research Ltd, Zogenix, LivaNova, Marinus Pharmaceuticals, and UCB. L.G.S. reports grants from Health Research Council of New Zealand, grants from Cure Kids New Zealand, during the conduct of the study; grants and personal fees from Zynerba, other from Sequirus, other from Nutricia, outside the submitted work. S.M.Z. has received research funding from Epilepsy Research UK, UCB Pharma, Glasgow Children’s Hospital Charity, Dravet Syndrome UK. He serves as Editor-in-Chief of <i>European Journal of Pediatric Neurology</i> for which he receives an honorarium from Elsevier Ltd. He has participated in educational symposia/advisory boards/consulted for GW Pharma, Zogenix Ltd, Biocodex, Nutricia, and Encoded Genomics. The other authors declare no conflicts of interest.
